✦ LIBER ✦

Combining the Anti-HER2 Antibody Trastuzumab with Taxanes in Breast Cancer: Results and Trial Considerations

✍ Scribed by Mark D. Pegram; Carminda O'Callaghan

Book ID: 119934592
Publisher: CIG Media Group, LP.
Year: 2001
Tongue: English
Weight: 102 KB
Volume: 2
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2001.s.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the Adjuvant Treatment of HE

Advances in the Adjuvant Treatment of HER2-Overexpressing Breast Cancer with the Anti-HER2 Antibody Trastuzumab

✍ Chris Schwab; Joyce A. O'Shaughnessy 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 467 KB

A phase 2 study of everolimus combined w

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

✍ Hurvitz, Sara A.; Dalenc, Florence; Campone, Mario; OâRegan, Ruth M.; Tjan-Hei 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 327 KB

Targeting endothelin A receptor enhances

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

✍ Jeanett Fischgräbe; Martin Götte; Katharina Michels; Ludwig Kiesel; Pia Wülfing 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 600 KB

Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in human breast cancers. It is known to drive tumor growth and progression and represents a prominent target in breast cancer therapy. The endothelin (ET) system, in particular ET-1 and its receptor ET A R, is of major relev

Antitumor activity of combinations of an

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models

✍ Kaori Fujimoto-Ouchi; Fumiko Sekiguchi; Yutaka Tanaka 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 114 KB

Efficacy and tolerability of taxanes or

Efficacy and tolerability of taxanes or vinorelbine chemotherapy with trastuzumab as a first combination in Her-2 overexpressing patients with metastatic breast cancer

✍ I. Glogowska; Sienkiewicz-Kozlowska; E. Szombara; T. Pienkowski 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Phase III trial of nonpegylated liposoma

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer

✍ Baselga, J.; Manikhas, A.; Cortes, J.; Llombart, A.; Roman, L.; Semiglazov, V. F 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 273 KB